BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 9208155)

  • 1. A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy.
    Colado MI; O'Shea E; Granados R; Misra A; Murray TK; Green AR
    Br J Pharmacol; 1997 Jun; 121(4):827-33. PubMed ID: 9208155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones.
    Sanchez V; O'shea E; Saadat KS; Elliott JM; Colado MI; Green AR
    J Psychopharmacol; 2004 Sep; 18(3):412-6. PubMed ID: 15358986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
    McNamara R; Kerans A; O'Neill B; Harkin A
    Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide.
    Freezer A; Salem A; Irvine RJ
    Brain Res; 2005 Apr; 1041(1):48-55. PubMed ID: 15804499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.
    Wang X; Baumann MH; Xu H; Rothman RB
    Synapse; 2004 Sep; 53(4):240-8. PubMed ID: 15266556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-tert-butyl-alpha-phenylnitrone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats.
    Yeh SY
    Synapse; 1999 Mar; 31(3):169-77. PubMed ID: 10029234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
    Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI
    Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
    Hewton R; Salem A; Irvine RJ
    Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1051-7. PubMed ID: 17714093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.
    Sanchez V; Camarero J; Esteban B; Peter MJ; Green AR; Colado MI
    Br J Pharmacol; 2001 Sep; 134(1):46-57. PubMed ID: 11522596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys.
    Insel TR; Battaglia G; Johannessen JN; Marra S; De Souza EB
    J Pharmacol Exp Ther; 1989 Jun; 249(3):713-20. PubMed ID: 2471824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function.
    Callaghan PD; Owens WA; Javors MA; Sanchez TA; Jones DJ; Irvine RJ; Daws LC
    J Neurochem; 2007 Feb; 100(3):617-27. PubMed ID: 17181558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine.
    Colado MI; O'Shea E; Granados R; Murray TK; Green AR
    Br J Pharmacol; 1997 Jul; 121(5):889-900. PubMed ID: 9222545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain.
    Zhang L; Shirayama Y; Shimizu E; Iyo M; Hashimoto K
    Eur J Pharmacol; 2006 Aug; 544(1-3):1-9. PubMed ID: 16859675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of acute brain tyrosine depletion on MDMA-induced changes in brain 5-HT.
    Rodsiri R; Green AR; Marsden CA; Fone KC
    J Psychopharmacol; 2010 Feb; 24(2):267-74. PubMed ID: 19965941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats.
    Clemens KJ; Cornish JL; Li KM; Hunt GE; McGregor IS
    Neuropharmacology; 2005 Aug; 49(2):195-207. PubMed ID: 15993443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT.
    Shankaran M; Yamamoto BK; Gudelsky GA
    Synapse; 2001 Apr; 40(1):55-64. PubMed ID: 11170222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine.
    Broening HW; Bacon L; Slikker W
    J Pharmacol Exp Ther; 1994 Oct; 271(1):285-93. PubMed ID: 7965726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDMA-induced serotonergic neurotoxicity enhances aggressiveness in low- but not high-aggressive rats.
    Wallinga AE; ten Voorde AM; de Boer SF; Koolhaas JM; Buwalda B
    Eur J Pharmacol; 2009 Sep; 618(1-3):22-7. PubMed ID: 19616536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
    Colado MI; Williams JL; Green AR
    Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.